Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab-Reference-Cited by-同舟云学术

Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab

Published:2023-09-25 Issue:6 Volume:29 Page:1661-1664
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Habay Capucine¹,Auditeau Claire¹²^ORCID,Blandinières Adeline²³^ORCID,Bentounes Nûn K¹,Lavenu‐Bombled Cécile²³,Harroche Annie⁴^ORCID,Bally Cecile⁴,Frenzel Laurent⁴^ORCID,Borgel Delphine¹²,Lasne Dominique¹²^ORCID

Affiliation:

1. Laboratoire d'Hématologie Biologique AP‐HP, Hôpital Necker Enfants Malades Paris France

2. Université Paris‐Saclay INSERM Hémostase inflammation thrombose HITh U1176 Le Kremlin‐Bicêtre France

3. Laboratoire d'Hématologie Biologique AP‐HP, Hôpital Bicêtre Le Kremlin‐Bicêtre France

4. Centre de Traitement de l'Hémophilie AP‐HP, Hôpital Necker Enfants Malades Paris France

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14873

Reference10 articles.

1. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)

3. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

4. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)

5. Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of heat treatment on emicizumab and an alternative approach to eliminate interfering FVIII activity prior to functional analysis;Hämostaseologie;2024-02